[Combination therapy with bi-weekly docetaxel and 5'-deoxy-5-fluorouridine for advanced gastric cancer].
Recently, new and promising antitumor agents such as TS-1, CPT-11, and taxanes have been widely used and have contributed to the survival of unresectable and recurrent gastric cancer patients. However, problems remain in the treatment for patients showing multi-drug resistance to those agents. We have experienced five patients with unresectable and recurrent gastric cancer, treated with combination therapy with bi-weekly docetaxel and 5'-deoxy-5-fluorouridine (5'-DFUR). The therapy was introduced as a 2nd, 3rd, 4th, and 6th chemotherapy regimen. Among five cases, one showed a moderate response and two exhibited stable disease, while two suffered progressive disease. Although the performance status at the start of the therapy was "2" in three cases and "1" in two cases, there were no serious adverse events in any case, and all patients were treated at an outpatient clinic. Three cases were introduced to the regimen as final treatment and survived for 209, 246, and 157 days, respectively. Combination therapy with bi-weekly docetaxel/5'-DFUR can be a promising regimen for gastric patients showing multi-drug resistance and poorer performance status.